|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | QIAGEN N.V. (Nasdaq:QGEN), a provider of sample and assay technologies for research in life sciences and molecular diagnostics. |
|---|---|
| Transferring Party | Digene Corp. (Nasdaq:DIGE), a leader in HPV-targeted molecular diagnostic testing products. |
| Sector | Diagnostics |
| Date | July 30, 2007 |
| Analysis Creates a global leader in molecular diagnostics, outside blood screening and viral load monitoring. Combines QIAGEN's leading technology portfolio and breadth of molecular diagnostic tests with Digene's leadership in the fast-growing HPV testing segment. Combined company estimated to have over $350m of molecular diagnostics revenues and more than $800m in revenues overall in '08. Deal value - $1.6b on Digene sales of $191.1m (8.4x) and EBITDA of $39.0 (41.0x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |